Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This add-on open-label randomised controlled pragmatic trial aims to:
1. evaluate the effect of add-on astragalus treatment on type 2 diabetic patients with
stage 2 to 3 chronic kidney disease and macroalbuminuria.
2. estimate treatment effect, variance, recruitment rate, attrition rate and change in
clinical manifestation including Chinese medicine syndrome for parameters optimisation
and feasibility assessment for a subsequent phase III randomised controlled trial.
3. assess response predictors for efficacy and safety among type 2 diabetic patients with
stage 2 to 3 chronic kidney disease and macroalbuminuria receiving add-on astragalus
treatment
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The University of Hong Kong
Collaborator:
School of Chinese Medicine, The University of Hong Kong